Ocular Therapeutix nets FDA panel meeting for eye surgery hydrogel

The FDA scheduled a panel meeting to discuss and vote on the premarket approval of Ocular Therapeutix's ReSure Sealant, a drug-delivering hydrogel device designed to protect the eye after cataract surgery. It would be the only FDA-approved sealant for ophthalmic use if it passes the Opthalmic Devices Panel scheduled for Sept. 19. "Our goal was to fill a void in the marketplace for a device that can enhance post-operative care of cataract patients by providing greater certainty of wound closure," Ocular CEO Amar Sawhney said. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…